Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,683 | 2,463 | 4,145 | 6,062 | 11,944 |
| Receivables | N/A | 4 | 1 | 1 | N/A |
| TOTAL | $3,550 | $4,678 | $6,037 | $8,261 | $12,869 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | 2 | 5,532 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 1,039 |
| TOTAL | $N/A | $N/A | $N/A | $2 | $6,571 |
| Total Assets | $3,550 | $4,678 | $6,037 | $8,263 | $19,440 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 458 | 365 | 597 | 616 | 1,298 |
| Accrued Expenses | 368 | 542 | 643 | 1,340 | 3,071 |
| TOTAL | $826 | $907 | $1,240 | $1,956 | $4,676 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 864 |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $864 |
| Total Liabilities | $826 | $907 | $1,240 | $1,956 | $5,540 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,601 | 1,601 | 1,601 | 1,601 | 1,605 |
| Common Shares | 2 | 2 | 16 | 2 | 241 |
| Retained earnings | -919,704 | -918,577 | -917,449 | -915,767 | -907,924 |
| TOTAL | $2,724 | $3,771 | $4,797 | $6,307 | $13,900 |
| Total Liabilities And Equity | $3,550 | $4,678 | $6,037 | $8,263 | $19,440 |